Skip to main content

Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomised controlled study

Javed, Zeeshan; Papageorgiou, Maria; Deshmukh, Harshal; Rigby, Alan S.; Qamar, Unaiza; Abbas, Jehangir; Khan, Amer Y; Khan, Amer Y.; Kilpatrick, Eric S; Kilpatrick, Eric S.; Atkin, Stephen L; Atkin, Stephen L.; Sathyapalan, Thozhukat

Authors

Zeeshan Javed

Maria Papageorgiou

Harshal Deshmukh

Alan S. Rigby

Unaiza Qamar

Jehangir Abbas

Amer Y Khan

Amer Y. Khan

Eric S Kilpatrick

Eric S. Kilpatrick

Stephen L Atkin

Stephen L. Atkin

Thozhukat Sathyapalan



Abstract

Background: Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs. metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS.
Materials and methods: A randomized open-label study was conducted in women with PCOS who were randomised to either empagliflozin 25mg (n=19) or metformin 1500mg (n=20) daily for 12 weeks. The main outcomes assessed were changes in anthropometric and body composition, hormonal and metabolic parameters.
Results: Univariate analysis showed significant differences in weight (empagliflozin: -1.4±3.2% vs. metformin: 1.2±2.3%; p=0.006), body mass index (empagliflozin: -1.4±3.2% vs. metformin: 1.1±2.2%; p=0.006), waist circumference (empagliflozin: -1.6±2.8% vs. metformin: 0.2±2.1%; p=0.029) and hip circumference (empagliflozin: -2.0±3.0% vs. metformin: 1.1±1.9%; p=0.001), basal metabolic rate (empagliflozin: -1.8±2.9% vs. metformin: 0.1±1.9%, p=0.024) and fat mass (empagliflozin: -0.7±4.9% vs. metformin, 3.2±5.0%; p=0.023) between the empagliflozin and the metformin groups. These differences were confirmed in linear regression analysis after adjustment for relevant covariates. There were no significant changes in hormonal or metabolic parameters between both groups.
Conclusion: There was a significant improvement in anthropometric parameters and body composition, in overweight and obese women with PCOS after 12 weeks of treatment with empagliflozin compared to metformin, although no changes were seen in hormonal or metabolic parameters.

Journal Article Type Article
Publication Date 2019-06
Journal Clinical Endocrinology
Print ISSN 0300-0664
Electronic ISSN 1365-2265
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 90
Issue 6
Pages 805-813
APA6 Citation Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., …Sathyapalan, T. (2019). Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomised controlled study. Clinical Endocrinology, 90(6), 805-813. https://doi.org/10.1111/cen.13968
DOI https://doi.org/10.1111/cen.13968
Keywords Body composition; Empagliflozin; Hormones; Metabolic parameters; Polycystic ovary syndrome; SGLT2 inhibitors
Publisher URL https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13968
;